News | November 07, 2022
Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
This first joint plan on One Health aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats
Periodic community awareness program through Aster’s DM Healthcare’s visual media and social media platforms and implementing TB control activity through Aster Pharmacies across South India
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
The need for hot-melt extrusion (HME) polymers is expected to grow as the pharma industry moves to implement more continuous and sustainable processes.
UNICEF award is worth US $98.755 million for supply of around 99.70 million doses during calendar years 2023-2027
The award was presented to Biocon Foundation as a mark of recognition of various projects undertaken during the year for reducing the environmental impact on cities
This acquisition will accelerate Medcare's plans to emerge as an international hub for health, beauty, and wellness adding to its existing network of 4 hospitals and over 20 medical centres in the UAE.
Subscribe To Our Newsletter & Stay Updated
